SCHEMBL259322

SCHEMBL259322

COc1cccc(-c2nc3nccnc3c(=O)[nH]2)c1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKA O14965 1/20 0.63
PARP1 P09874 1/20 0.51
HPGD P15428 2/20 0.50
MEN1 O00255 1/20 0.50
HTT P42858 1/20 0.50
KMT2A Q03164 1/20 0.50
NPSR1 Q6W5P4 1/20 0.50
NR1I2 O75469 1/20 0.49
CYP1A2 P05177 1/20 0.49
VDR P11473 1/20 0.49
CYP2C9 P11712 1/20 0.49
CYP2B6 P20813 1/20 0.49
AHR P35869 1/20 0.49
NR1I3 Q14994 1/20 0.49
PIN1 Q13526 1/20 0.49
BRD4 O60885 1/20 0.48
KDM4E B2RXH2 2/20 0.48
ALDH1A1 P00352 2/20 0.48
NPC1 O15118 1/20 0.47
GAA P10253 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL259498 0.85 AURKA (0.46) AURKAPARP1PIN1KDM4EALDH1A1
SCHEMBL259317 0.85 AURKA (0.60) AURKAHPGDMEN1HTTKMT2A
SCHEMBL10741718 0.81 AURKA (0.69) AURKAPARP1NR1I2CYP1A2VDR
SCHEMBL2125639 0.80 GAA (0.50) PARP1PIN1BRD4KDM4EALDH1A1
SCHEMBL2130092 0.80 MGAM (0.50) AURKAPARP1PIN1GAA
SCHEMBL12112024 0.78 AURKA (0.54) AURKAHPGDMEN1HTTKMT2A
SCHEMBL2128325 0.77 KDM4E (0.53) PARP1HPGDMEN1HTTKMT2A
SCHEMBL874228 0.74 GUSB (0.73) PARP1CYP1A2NPC1RAB9A
SCHEMBL29784145 0.74 GUSB (0.73) PARP1CYP1A2NPC1RAB9A
SCHEMBL259622 0.72 KDM4C (0.55) PARP1HPGDMEN1HTTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8067586-B2 Fused heteroaryl derivatives ASTELLAS PHARMA INC. (JP) 2011-11-29 US disclosed
US-8067586-B2 Fused heteroaryl derivatives ASTELLAS PHARMA INC. (JP) 2011-11-29 US disclosed
US-20100137584-A1 FUSED HETEROARYL DERIVATIVES HAYAKAWA MASAHIKO 2010-06-03 US disclosed
US-20100137584-A1 FUSED HETEROARYL DERIVATIVES HAYAKAWA MASAHIKO 2010-06-03 US disclosed
US-20100137585-A1 FUSED HETEROARYL DERIVATIVES HAYAKAWA MASAHIKO 2010-06-03 US disclosed
US-20100137585-A1 FUSED HETEROARYL DERIVATIVES HAYAKAWA MASAHIKO 2010-06-03 US disclosed
US-20070037805-A1 Fused heteroaryl derivatives HAYAKAWA MASAHIKO 2007-02-15 US disclosed
US-20070037805-A1 Fused heteroaryl derivatives HAYAKAWA MASAHIKO 2007-02-15 US disclosed
US-7173029-B2 Fused heteroaryl derivatives ASTELLAS PHARMA INC. (JP) 2007-02-06 US disclosed
US-7173029-B2 Fused heteroaryl derivatives ASTELLAS PHARMA INC. (JP) 2007-02-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137584-A1 FUSED HETEROARYL DERIVATIVES PIK3CD, PIK3R3, PIK3C2A AURKA 113/4885PARP1 1165/4885HPGD 4466/4885
US-20070037805-A1 Fused heteroaryl derivatives PIK3CD, PIK3R3, PIK3C2A AURKA 113/4885PARP1 1165/4885HPGD 4466/4885
US-20100137585-A1 FUSED HETEROARYL DERIVATIVES PIK3CD, PIK3R3, PIK3C2A AURKA 113/4885PARP1 1165/4885HPGD 4466/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.